Korean J healthc assoc Infect Control Prev.  2020 Dec;25(2):86-99. 10.14192/kjicp.2020.25.2.86.

Fundamentals of Mycology for Infection Control and Prevention

• Lee R
• Cho SY
• Lee DG

• KMID: 2510134
• DOI: http://doi.org/10.14192/kjicp.2020.25.2.86

Abstract

Fungal infections have become more important in the clinical field because of the increasing number of immunocompromised patients, such as cancer patients undergoing chemotherapy, transplantation recipients undergoing immunosuppressive therapy, and patients needing critical care, as well as the widespread use of invasive devices such as central venous catheters. Moreover, the current emphasis on antimicrobial prophylaxis has contributed to the changing epidemiology and antifungal resistance of invasive fungal infections. This article focuses on invasive candidiasis, aspergillosis, and mucormycosis, giving a brief overview regarding the clinical manifestations, recent epidemiology, pathogenesis, diagnosis and treatment, and recent healthcare-associated infection topics. Basic concepts and strategies of infection control for clinically important fungi are also summarized in this article.

Keyword

Yeast; Fungi; Infection control

Reference

1. Edward JE Jr. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. 2018. Diagnosis and treatment of fungal infections. Harrison's principles of internal medicine. 20th ed. McGraw-Hill Education;New York: p. 1515–8.

2. McNeil MM, Chiller TM. Mayhall CG, editor. 2012. Candida. Hospital epidemiology and infection control. 4th ed. Lippincott Williams & Wilkins;Philadelphia: p. 609–27.

3. Ostrosky-Zeichner L, Rex JH. Mayhall CG, editor. 2012. Filamentous fungi. Hospital epidemiology and infection con­trol. 4th ed. Lippincott Williams & Wilkins;Philadelphia: p. 628–31.

4. Kullberg BJ, Arendrup MC. 2015; Invasive candidiasis. N Engl J Med. 373:1445–56. DOI: 10.1056/NEJMra1315399. PMID: 26444731.

5. Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, et al. 2014; Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med. 40:1303–12. DOI: 10.1007/s00134-014-3408-3. PMID: 25097069. PMCID: PMC4147247.

6. McCarty TP, Pappas PG. 2016; Invasive candidiasis. Infect Dis Clin North Am. 30:103–24. DOI: 10.1016/j.idc.2015.10.013. PMID: 26739610.

7. Antinori S, Milazzo L, Sollima S, Galli M, Corbellino M. 2016; Candidemia and invasive candidiasis in adults: a narrative review. Eur J Intern Med. 34:21–8. DOI: 10.1016/j.ejim.2016.06.029. PMID: 27394927.

8. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. 2018; Invasive candidiasis. Nat Rev Dis Primers. 4:18026. DOI: 10.1038/nrdp.2018.26. PMID: 29749387.

9. Jung SI, Shin JH, Song JH, Peck KR, Lee K, Kim MN, et al. 2010; Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. Med Mycol. 48:669–74. DOI: 10.3109/13693780903410386. PMID: 20392145.

10. Ko JH, Jung DS, Lee JY, Kim HA, Ryu SY, Jung SI, et al. 2019; Changing epidemiology of non-albicans candidemia in Korea. J Infect Chemother. 25:388–91. DOI: 10.1016/j.jiac.2018.09.016. PMID: 30482698.

11. Fan D, Coughlin LA, Neubauer MM, Kim J, Kim MS, Zhan X, et al. 2015; Activation of HIF-1α and LL-37 by commensal bacteria inhibits Candida albicans colonization. Nat Med. 21:808–14. DOI: 10.1038/nm.3871. PMID: 26053625. PMCID: PMC4496259.

12. Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, et al. 2017; Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol. 55:2996–3005. DOI: 10.1128/JCM.00921-17. PMID: 28747370. PMCID: PMC5625385.

13. Clancy CJ, Nguyen MH. 2013; Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 56:1284–92. DOI: 10.1093/cid/cit006. PMID: 23315320.

14. Avni T, Leibovici L, Paul M. 2011; PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 49:665–70. DOI: 10.1128/JCM.01602-10. PMID: 21106797. PMCID: PMC3043518.

15. Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ. 2013; Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother. 57:3528–35. DOI: 10.1128/AAC.00136-13. PMID: 23669387. PMCID: PMC3719767.

16. Arendrup MC, Perlin DS. 2014; Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis. 27:484–92. DOI: 10.1097/QCO.0000000000000111. PMID: 25304391. PMCID: PMC4221099.

17. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, et al. 2013; Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 56:1724–32. DOI: 10.1093/cid/cit136. PMID: 23487382. PMCID: PMC3658363.

18. Cleveland AA, Harrison LH, Farley MM, Hollick R, Stein B, Chiller TM, et al. 2015; Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One. 10:e0120452. DOI: 10.1371/journal.pone.0120452. PMID: 25822249. PMCID: PMC4378850.

19. Suleyman G, Alangaden GJ. 2016; Nosocomial fungal infections: epidemiology, infection control, and prevention. Infect Dis Clin North Am. 30:1023–52. DOI: 10.1016/j.idc.2016.07.008. PMID: 27816138.

20. Kaur H, Shankarnarayana SA, Hallur V, Muralidharan J, Biswal M, Ghosh AK, et al. 2020; Prolonged outbreak of Candida krusei candidemia in paediatric ward of tertiary care hospital. Mycopathologia. 185:257–68. DOI: 10.1007/s11046-020-00427-y. PMID: 31983047. PMCID: PMC7222167.

21. Qi L, Fan W, Xia X, Yao L, Liu L, Zhao H, et al. 2018; Nosocomial outbreak of Candida parapsilosis sensu stricto fungaemia in a neonatal intensive care unit in China. J Hosp Infect. 100:e246–52. DOI: 10.1016/j.jhin.2018.06.009. PMID: 29928941.

22. Chowdhary A, Sharma C, Meis JF. 2017; Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 13:e1006290. DOI: 10.1371/journal.ppat.1006290. PMID: 28542486. PMCID: PMC5436850.

23. Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, et al. 2011; First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 49:3139–42. DOI: 10.1128/JCM.00319-11. PMID: 21715586. PMCID: PMC3165631.

24. Ku TSN, Walraven CJ, Lee SA. 2018; Candida auris: disinfectants and implications for infection control. Front Microbiol. 9:726. DOI: 10.3389/fmicb.2018.00726. PMID: 29706945. PMCID: PMC5906573.

25. Caceres DH, Forsberg K, Welsh RM, Sexton DJ, Lockhart SR, Jackson BR, et al. 2019; Candida auris: a review of re­commendations for detection and control in healthcare settings. J Fungi (Basel). 5:111. DOI: 10.3390/jof5040111. PMID: 31795175. PMCID: PMC6958335.

26. Healthcare Infection Control Practices Advisory Committee (HICPAC). Core infection prevention and control practices for safe healthcare delivery in all settings - recommendations of the HICPAC. Core infection prevention and control practices for safe healthcare delivery in all settings - recommendations of the HICPAC. https://www.cdc.gov/hicpac/pdf/core-practices.pdf . Updated on 15 March 2017.

27. Saiman L, Ludington E, Dawson JD, Patterson JE, Rangel-Frausto S, Wiblin RT, et al. 2001; Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J. 20:1119–24. DOI: 10.1097/00006454-200112000-00005. PMID: 11740316.

28. Jung J, Moon YS, Yoo JA, Lim JH, Jeong J, Jun JB. 2018; Investigation of a nosocomial outbreak of fungemia caused by Candida pelliculosa (Pichia anomala) in a Korean tertiary care center. J Microbiol Immunol Infect. 51:794–801. DOI: 10.1016/j.jmii.2017.05.005. PMID: 28779880.

29. Asensio A, Muñez E, Cantero M, Ramos A. 2015; Candida guilliermondii fungemia in hospitalized patients epidemiologically linked to a patient care attendant. Am J Infect Control. 43:1012–4. DOI: 10.1016/j.ajic.2015.04.207. PMID: 26052104.

30. Xiao M, Wang H, Lu J, Chen SC, Kong F, Ma XJ, et al. 2014; Three clustered cases of candidemia caused by Candida quercitrusa and mycological characteristics of this novel species. J Clin Microbiol. 52:3044–8. DOI: 10.1128/JCM.00246-14. PMID: 24696025. PMCID: PMC4136143.

31. Pinhati HM, Casulari LA, Souza AC, Siqueira RA, Damasceno CM, Colombo AL. 2016; Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit. BMC Infect Dis. 16:433. DOI: 10.1186/s12879-016-1767-9. PMID: 27544427. PMCID: PMC4992558.

32. Haciseyitoğlu D, Çağ Y. 2019; An outbreak of candidemia due to Candida parapsilosis in an adult intensive care unit. Infez Med. 27:403–9.

33. Calvo B, Melo AS, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F, et al. 2016; First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Infect. 73:369–74. DOI: 10.1016/j.jinf.2016.07.008. PMID: 27452195.

34. Guo W, Gu HF, Zhang HG, Chen SB, Wang JQ, Geng SX, et al. 2015; An outbreak of Candida parapsilosis fungemia among preterm infants. Genet Mol Res. 14:18259–67. DOI: 10.4238/2015.December.23.13. PMID: 26782473.

35. Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, et al. 2016; First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 5:35. DOI: 10.1186/s13756-016-0132-5. PMID: 27777756. PMCID: PMC5069812.

36. Calà C, Fontana I, Di Carlo P, Mascarella C, Fasciana T, Reale S, et al. 2020; Candida parapsilosis infection: a multilocus microsatellite genotyping-based survey demonstrating an outbreak in hospitalized patients. Ann Clin Lab Sci. 50:657–64.

37. Taori SK, Khonyongwa K, Hayden I, Athukorala GDA, Letters A, Fife A, et al. 2019; Candida auris outbreak: mortality, interventions and cost of sustaining control. J Infect. 79:601–11. DOI: 10.1016/j.jinf.2019.09.007. PMID: 31557493.

38. Ruiz-Gaitán A, Moret AM, Tasias-Pitarch M, Aleixandre-López AI, Martínez-Morel H, Calabuig E, et al. 2018; An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses. 61:498–505. DOI: 10.1111/myc.12781. PMID: 29655180.

39. Chowdhary A, Stielow JB, Upadhyaya G, Singh PK, Singh A, Meis JF. 2020; Candida blankii: an emerging yeast in an outbreak of fungaemia in neonates in Delhi, India. Clin Microbiol Infect. 26:648. e5-8. DOI: 10.1016/j.cmi.2020.01.001. PMID: 31927114.

40. Biswal M, Rudramurthy SM, Jain N, Shamanth AS, Sharma D, Jain K, et al. 2017; Controlling a possible outbreak of Candida auris infection: lessons learnt from multiple interventions. J Hosp Infect. 97:363–70. DOI: 10.1016/j.jhin.2017.09.009. PMID: 28939316.

41. Theodoropoulos NM, Bolstorff B, Bozorgzadeh A, Brandeburg C, Cumming M, Daly JS, et al. 2020; Candida auris outbreak involving liver transplant recipients in a surgical intensive care unit. Am J Transplant. 20:3673–9. DOI: 10.1111/ajt.16144. PMID: 32530145.

42. Sana F, Hussain W, Zaman G, Satti L, Khurshid U, Khadim MT. 2019; Candida auris outbreak report from Pakistan: a success story of infection control in ICUs of a tertiary care hospital. J Hosp Infect. 103:108–10. DOI: 10.1016/j.jhin.2019.06.011. PMID: 31233850.

43. Al Maani A, Paul H, Al-Rashdi A, Wahaibi AA, Al-Jardani A, Al Abri AMA, et al. 2019; Ongoing challenges with healthcare-associated Candida auris outbreaks in Oman. J Fungi (Basel). 5:101. DOI: 10.3390/jof5040101. PMID: 31652825. PMCID: PMC6958405.

44. Alshamrani MM, El-Saed A, Mohammed A, Alghoribi MF, Al Johani SM, Cabanalan H, et al. Management of Candida auris outbreak in a tertiary-care setting in Saudi Arabia. Infect Control Hosp Epidemiol. in press 2020. DOI: 10.1017/ice.2020.414. PMID: 32880247.

45. Barac A, Cevik M, Colovic N, Lekovic D, Stevanovic G, Micic J, et al. 2020; Investigation of a healthcare-associated Candida tropicalis candidiasis cluster in a haematology unit and a systematic review of nosocomial outbreaks. Mycoses. 63:326–33. DOI: 10.1111/myc.13048. PMID: 31930592.

46. Guducuoglu H, Gultepe B, Otlu B, Bektas A, Yildirim O, Tuncer O, et al. 2016; Candida albicans outbreak associated with total parenteral nutrition in the neonatal unit. Indian J Med Microbiol. 34:202–7. DOI: 10.4103/0255-0857.180303. PMID: 27080773.

47. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. 2017; Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 64:134–40. DOI: 10.1093/cid/ciw691. PMID: 27988485. PMCID: PMC5215215.

48. Marcos-Zambrano LJ, Escribano P, Sanguinetti M, Gómez G de la Pedrosa E, De Carolis E, Vella A, et al. 2015; Clusters of patients with candidaemia due to genotypes of Candida albicans and Candida parapsilosis: differences in frequency between hospitals. Clin Microbiol Infect. 21:677–83. DOI: 10.1016/j.cmi.2015.03.007. PMID: 25882359.

49. Ture Z, Alp E. 2018; Infection control measures to prevent hospital transmission of candida. Hosp Pract (1995). 46:253–7. DOI: 10.1080/21548331.2018.1510282. PMID: 30102587.

50. Entesari-Tatafi D, Orford N, Bailey MJ, Chonghaile MN, Lamb-Jenkins J, Athan E. 2015; Effectiveness of a care bundle to reduce central line-associated bloodstream infections. Med J Aust. 202:247–50. DOI: 10.5694/mja14.01644. PMID: 25758694.

51. Munoz-Price LS, Hota B, Stemer A, Weinstein RA. 2009; Prevention of bloodstream infections by use of daily chlorhexidine baths for patients at a long-term acute care hospital. Infect Control Hosp Epidemiol. 30:1031–5. DOI: 10.1086/644751. PMID: 19751155.

52. Martín-Gutiérrez G, Peñalva G, Aguilar M, Ruiz-Pérez de Pipaón M, Gil-Navarro MV, Pérez-Blanco JL, et al. 2020; Efficacy and safety of a comprehensive educational antimicrobial stewardship program focused on antifungal use. J Infect. 80:342–9. DOI: 10.1016/j.jinf.2020.01.002. PMID: 31954101.

53. Bielska E, May RC. 2016; What makes Cryptococcus gattii a pathogen? FEMS Yeast Res. 16:fov106. DOI: 10.1093/femsyr/fov106. PMID: 26614308.

54. Iatta R, Cafarchia C, Cuna T, Montagna O, Laforgia N, Gentile O, et al. 2014; Bloodstream infections by Malassezia and Candida species in critical care patients. Med Mycol. 52:264–9. DOI: 10.1093/mmy/myt004. PMID: 24576998.

55. Kanamori H, Weber DJ, Rutala WA. 2016; Healthcare outbreaks associated with a water reservoir and infection prevention strategies. Clin Infect Dis. 62:1423–35. DOI: 10.1093/cid/ciw122. PMID: 26936670.

56. Cadena J, Thompson GR 3rd, Patterson TF. 2016; Invasive aspergillosis: current strategies for diagnosis and management. Infect Dis Clin North Am. 30:125–42. DOI: 10.1016/j.idc.2015.10.015. PMID: 26897064.

57. Marr KA, Patterson T, Denning D. 2002; Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am. 16:875–94. vi. DOI: 10.1016/S0891-5520(02)00035-1.

58. Chou EH, Mann S, Hsu TC, Hsu WT, Liu CC, Bhakta T, et al. 2020; Incidence, trends, and outcomes of infection sites among hospitalizations of sepsis: a nationwide study. PLoS One. 15:e0227752. DOI: 10.1371/journal.pone.0227752. PMID: 31929577. PMCID: PMC6957188.

59. Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, et al. 2014; Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis. 20:1149–55. DOI: 10.3201/eid2007.140087. PMID: 24960557. PMCID: PMC4073874.

60. Vallabhaneni S, Benedict K, Derado G, Mody RK. 2017; Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000-2013. Open Forum Infect Dis. 4:ofw268. DOI: 10.1093/ofid/ofw268. PMID: 28480260. PMCID: PMC5413990.

61. Huh K, Ha YE, Denning DW, Peck KR. 2017; Serious fungal infections in Korea. Eur J Clin Microbiol Infect Dis. 36:957–63. DOI: 10.1007/s10096-017-2923-x. PMID: 28161743.

62. Rolston KV. 2004; The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis. 39(Suppl 1):S44–8. DOI: 10.1086/383053. PMID: 15250020.

63. Choi JK, Cho SY, Yoon SS, Moon JH, Kim SH, Lee JH, et al. 2017; Epidemiology and risk factors for invasive fungal diseases among allogeneic hematopoietic stem cell transplant recipients in Korea: results of "RISK" study. Biol Blood Marrow Transplant. 23:1773–9. DOI: 10.1016/j.bbmt.2017.06.012. PMID: 28668492.

64. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. 2020; Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 71:1367–76. DOI: 10.1093/cid/ciz1008. PMID: 31802125. PMCID: PMC7486838.

65. Cho SY, Lee DG, Choi JK, Lee HJ, Kim SH, Park SH, et al. 2017; Characteristics of culture-positive invasive pulmonary aspergillosis in patients with hematologic diseases: comparison between Aspergillus fumigatus and non-fumigatus Aspergillus species. Medicine (Baltimore). 96:e8841. DOI: 10.1097/MD.0000000000008841. PMID: 29245249. PMCID: PMC5728864.

66. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. 2016; Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 63:e1–60. DOI: 10.1093/cid/ciw326. PMID: 27365388. PMCID: PMC4967602.

67. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. 2002; Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 347:408–15. DOI: 10.1056/NEJMoa020191. PMID: 12167683.

68. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Amé S, Fohrer C, et al. 2008; Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 47:1176–84. DOI: 10.1086/592255. PMID: 18808352.

69. Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. 2018; Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 24(Suppl 1):e1–38. DOI: 10.1016/j.cmi.2018.01.002. PMID: 29544767.

70. Maertens JA, Raad II II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. 2016; Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 387:760–9. DOI: 10.1016/S0140-6736(15)01159-9.

71. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, et al. 2009; Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 15:1068–76. DOI: 10.3201/eid1507.090043. PMID: 19624922. PMCID: PMC2744247.

72. Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, et al. , van der Linden JW. 2011; Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis. 17:1846–54. DOI: 10.3201/eid1710.110226. PMID: 22000354. PMCID: PMC3311118.

73. Cho SY, Lee DG, Kim WB, Chun HS, Park C, Myong JP, et al. 2019; Epidemiology and antifungal susceptibility profile of Aspergillus species: comparison between environmental and clinical isolates from patients with hematologic malignancies. J Clin Microbiol. 57:e02023–18. DOI: 10.1128/JCM.02023-18. PMID: 31018982. PMCID: PMC6595445.

74. Verweij PE, Zhang J, Debets AJM, Meis JF, Schoustra SE, et al. , van de Veerdonk FL. 2016; In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. Lancet Infect Dis. 16:e251–60. DOI: 10.1016/S1473-3099(16)30138-4.

75. Centers for Disease Control and Prevention. Mucormycosis. Mucormycosis. https://www.cdc.gov/fungal/diseases/mucormycosis/definition.html . Updated on May 26 2020.

76. Legouge C, Caillot D, Chrétien ML, Lafon I, Ferrant E, Audia S, et al. 2014; The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin Infect Dis. 58:672–8. DOI: 10.1093/cid/cit929. PMID: 24352351.

77. Maturu VN, Agarwal R. 2014; Reversed halo sign: a systematic review. Respir Care. 59:1440–9. DOI: 10.4187/respcare.03020. PMID: 24782557.

78. Devauchelle P, Jeanne M, Fréalle E. 2019; Mucormycosis in burn patients. J Fungi (Basel). 5:25. DOI: 10.3390/jof5010025. PMID: 30901836. PMCID: PMC6463177.

79. Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al. 2016; Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 16:828–37. DOI: 10.1016/S1473-3099(16)00071-2.

80. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. 2019; Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 19:e405–21.

81. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. 2007; In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother. 51:2587–90. DOI: 10.1128/AAC.00452-07. PMID: 17452481. PMCID: PMC1913247.

82. Guinea J, Escribano P, Vena A, Muñoz P, Martínez-Jiménez MDC, Padilla B, et al. 2017; Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: epidemiology and microbiological characterization of the isolates. PLoS One. 12:e0179136. DOI: 10.1371/journal.pone.0179136. PMID: 28591186. PMCID: PMC5462442.

83. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. 2005; Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 41:634–53. DOI: 10.1086/432579. PMID: 16080086.

84. Maraví-Poma E, Rodríguez-Tudela JL, de Jalón JG, Manrique-Larralde A, Torroba L, Urtasun J, et al. 2004; Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. Intensive Care Med. 30:724–8. DOI: 10.1007/s00134-003-2132-1. PMID: 14991098.

85. Chaves MS, Franco D, Nanni JC, Basaldúa ML, Boleas M, Aphalo G, et al. 2016; Control of an outbreak of postoperative bone mucormycosis: an intervention study of contiguous cohorts. Am J Infect Control. 44:1715–7. DOI: 10.1016/j.ajic.2016.06.017. PMID: 27499195.

86. Gamarra S, Chaves MS, Cabeza MS, Macedo D, Leonardelli F, Franco D, et al. 2018; Mucormycosis outbreak due to Rhizopus microsporus after arthroscopic anterior cruciate ligament reconstruction surgery evaluated by RAPD and MALDI-TOF Mass spectrometry. J Mycol Med. 28:617–22. DOI: 10.1016/j.mycmed.2018.09.002. PMID: 30249460.

87. Anaissie EJ, Kuchar RT, Rex JH, Francesconi A, Kasai M, Müller FM, et al. 2001; Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis. 33:1871–8. DOI: 10.1086/324501. PMID: 11692299.

88. Patterson JE, Zidouh A, Miniter P, Andriole VT, Patterson TF. 1997; Hospital epidemiologic surveillance for invasive aspergillosis: patient demographics and the utility of antigen detection. Infect Control Hosp Epidemiol. 18:104–8. DOI: 10.2307/30142398. PMID: 9120237.

89. Peláez T, Muñoz P, Guinea J, Valerio M, Giannella M, Klaassen CH, et al. 2012; Outbreak of invasive aspergillosis after major heart surgery caused by spores in the air of the intensive care unit. Clin Infect Dis. 54:e24–31. DOI: 10.1093/cid/cir771. PMID: 22247307.

90. Park JH, Ryu SH, Lee JY, Kim HJ, Kwak SH, Jung J, et al. 2019; Airborne fungal spores and invasive aspergillosis in hematologic units in a tertiary hospital during construction: a prospective cohort study. Antimicrob Resist Infect Control. 8:88. DOI: 10.1186/s13756-019-0543-1. PMID: 31161035. PMCID: PMC6542016.

91. La Milia DI, Vincenti S, Fiori B, Pattavina F, Torelli R, Barbara A, et al. 2019; Monitoring of particle environmental pollution and fungal isolations during hospital building-work activities in a hematology ward. Mediterr J Hematol Infect Dis. 11:e2019062. DOI: 10.4084/mjhid.2019.062. PMID: 31700587. PMCID: PMC6827607.

92. Golan JJ, Pringle A. Long-distance dispersal of fungi. Microbiol Spectr. in press 2017. DOI: 10.1128/9781555819583.ch14.

93. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. 2009; Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 15:1143–238. DOI: 10.1016/j.bbmt.2009.06.019. PMID: 19747629. PMCID: PMC3103296.

94. Chang CC, Ananda-Rajah M, Belcastro A, McMullan B, Reid A, Dempsey K, et al. 2014; Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014. Intern Med J. 44:1389–97. DOI: 10.1111/imj.12601. PMID: 25482747.

95. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. 2007; Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 356:348–59. DOI: 10.1056/NEJMoa061094. PMID: 17251531.

96. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. 2007; Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 356:335–47. DOI: 10.1056/NEJMoa061098. PMID: 17251530.